Relapsing MS patients more satisfied with Novartis oral drug Gilenya(TM) than standard injectable therapies, according to new study results at CMSC
Market Watch, The Wall Street Journal, 30 May 2013
Accessed on 31 May 2013 from http://www.marketwatch.com/story/relapsing-ms-patients-more-satisfied-with-novartis-oral-drug-gilenya-than-standard-injectable-therapies-according-to-new-study-results-at-cmsc-2013-05-30.